HOSPITAL UNIVERSITARIO RUBER
Department
Hospital Ramón y Cajal
Madrid, EspañaPublications in collaboration with researchers from Hospital Ramón y Cajal (136)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment
-
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
International Journal of Molecular Sciences, Vol. 25, Núm. 7
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
-
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
Frontiers in Oncology, Vol. 13
-
Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response
Frontiers in Immunology, Vol. 14
-
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
International Journal of Molecular Sciences, Vol. 24, Núm. 15
-
Recommendations to standardize patients' follow-up after interventional procedures in chronic pain treatment: A Delphi study
Pain Practice, Vol. 23, Núm. 6, pp. 618-625
-
Top advances of the year: Breast cancer
Cancer
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases
Cancers, Vol. 14, Núm. 5
-
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567
-
Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”
Cancers, Vol. 14, Núm. 21
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1
-
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
International Journal of Infectious Diseases, Vol. 123, pp. 97-103
-
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Nature Communications, Vol. 13, Núm. 1
2021
-
A novel circulating microRNA for the detection of acute myocarditis
New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027
-
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Breast Cancer Research, Vol. 23, Núm. 1